A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Gene Therapy

• Publication date

  2008-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/gt.2008.121PMID 18701918
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oncolytic Viruses

  2020cited by this paper
• Xeroderma Pigmentosum

  2016cited by this paper
• HveC (nectin-1) is expressed at high levels in sensory neurons, but not in motor neurons, of the rat peripheral nervous system

  2011cited by this paper
• Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma

  2008cited by this paper
• A Herpes Simplex Virus Recombinant That Exhibits a Single-Chain Antibody to HER2/neu Enters Cells through the Mammary Tumor Receptor, Independently of the gD Receptors

  2006cited by this paper
• Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor

  2006cited by this paper
• Characterization of a Recombinant Herpes Simplex Virus 1 Designed To Enter Cells via the IL13Rα2 Receptor of Malignant Glioma Cells

  2005cited by this paper
• Herpes Simplex Virus Type 1 Strain HSV1716 Grown in Baby Hamster Kidney Cells Has Altered Tropism for Nonpermissive Chinese Hamster Ovary Cells Compared to HSV1716 Grown in Vero Cells

  2005cited by this paper
• Oncolytic viral therapies – the clinical experience

  2005cited by this paper
• Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy

  2005cited by this paper
• Future prospects for oncolytic therapy

  2005cited by this paper
• Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule.

  2005cited by this paper
• Vector integration: Location, location, location

  2005cited by this paper
• Cell Type–Specific Targeting with Sindbis Pseudotyped Lentiviral Vectors Displaying Anti-CCR5 Single-Chain Antibodies

  2005cited by this paper
• Efficient retroviral vector targeting of carcinoembryonic antigen-positive tumors.

  2004cited by this paper
• Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide

  2004cited by this paper
• Retargeting of adenoviral infection to melanoma: Combining genetic ablation of native tropism with a recombinant bispecific single‐chain diabody (scDb) adapter that binds to fiber knob and HMWMAA

  2004cited by this paper
• HSV-1 virions engineered for specific binding to cell surface receptors.

  2004cited by this paper
• The soluble ectodomain of herpes simplex virus gD contains a membrane-proximal pro-fusion domain and suffices to mediate virus entry.

  2004cited by this paper
• HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

  2004cited by this paper
• Antibody against the c-Met

  2004cited by this paper
• Herpes simplex virus: receptors and ligands for cell entry

  2004cited by this paper
• Entry of Herpes Simplex Virus Type 1 into Primary Sensory Neurons In Vitro Is Mediated by Nectin-1/HveC

  2003cited by this paper
• Ligand-directed targeting of genes to the site of disease

  2003cited by this paper
• Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met

  2003cited by this paper
• An oncolytic measles virus engineered to enter cells through the CD20 antigen.

  2003cited by this paper
• Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors

  2003cited by this paper
• Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.

  2003cited by this paper
• Herpesvirus Entry: an Update

  2003cited by this paper
• Engineered herpes simplex virus 1 is dependent on IL13Rα2 receptor for cell entry and independent of glycoprotein D receptor interaction

  2002cited by this paper
• Oncolytic viruses

  2002cited by this paper
• Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells

  2002cited by this paper
• The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

  2002cited by this paper
• Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105).

  2001cited by this paper
• Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase.

  2001cited by this paper
• Intralesional injection of herpes simplex virus 1716 in metastatic melanoma.

  2001cited by this paper
• Transcription from the gene encoding the herpesvirus entry receptor nectin-1 (HveC) in nervous tissue of adult mouse.

  2001cited by this paper
• Targeting of adenoviral vectors through a bispecific single-chain antibody

  2000cited by this paper
• Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

  2000cited by this paper
• Retrovirus Targeting by Tropism Restriction to Melanoma Cells

  1999cited by this paper
• Recurrent Malignant Gliomas Treated with Radiosurgery

  1999cited by this paper
• The Ectodomain of a Novel Member of the Immunoglobulin Subfamily Related to the Poliovirus Receptor Has the Attributes of a Bona Fide Receptor for Herpes Simplex Virus Types 1 and 2 in Human Cells

  1998cited by this paper
• Recombinant Herpes Simplex Virus Type 1 Engineered for Targeted Binding to Erythropoietin Receptor-Bearing Cells

  1998cited by this paper
• The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery

  1997cited by this paper
• Antibody engineering: a practical approach

  1997cited by this paper
• Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting.

  1997cited by this paper
• The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34

  1997cited by this paper
• Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins

  1996cited by this paper
• Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family.

  1996cited by this paper
• Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2.

  1994cited by this paper
• Herpes simplex virus type 1 ribonucleotide reductase large subunit: regions of the protein essential for subunit interaction and dimerization.

  1993cited by this paper
• Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence.

  1991cited by this paper

• Oncolytic Viruses as Cancer Therapeutics: From Mechanistic Insights to Clinical Translation.

  2025cites this paper
• Modern Approaches to Enterovirus-Based Oncolytic Immune Virotherapy of Malignant Diseases

  2025cites this paper
• Emerging delivery strategy for oncolytic virotherapy

  2024cites this paper
• HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib In Vitro and Significantly Reduces Systemic Tumor Growth in Mouse Models

  2023cites this paper
• The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles

  2023cites this paper
• Nanobugs as Drugs: Bacterial Derived Nanomagnets Enhance Tumor Targeting and Oncolytic Activity of HSV-1 Virus.

  2022cites this paper
• Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability

  2022cites this paper
• Los virus ¿un paso hacia delante en la evolución?

  2022cites this paper
• Identification of 22 Novel Motifs of the Cell Entry Fusion Glycoprotein B of Oncolytic Herpes Simplex Viruses: Sequence Analysis and Literature Review

  2020cites this paper
• Immunotherapeutic Challenges for Pediatric Cancers

  2019cites this paper
• Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses

  2018cites this paper
• High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy

  2018cites this paper
• Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

  2018cites this paper
• Oncolytic Viruses—Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer

  2017cites this paper
• The renaissance of anti‐neoplastic immunity from tumor cell demise

  2017cites this paper
• Construction of Various γ34.5 Deleted Fluorescent-Expressing Oncolytic herpes Simplex type 1 (oHSV) for Generation and Isolation of HSV-Based Vectors

  2017cites this paper
• Retargeting of herpes simplex virus (HSV) vectors.

  2016cites this paper
• Pancreatic cancer from bench to bedside: molecular pathways and treatment options.

  2016cites this paper
• Development of a novel nanoparticle bioconjugation strategy utilizing coiled-coil protein domains

  2016cites this paper
• Enhancement of oncolytic herpes simplex type 1 virotherapy

  2016cites this paper
• Oncolytic virotherapy for urological cancers

  2016cites this paper
• Recent progress in protein-protein interaction study for EGFR-targeted therapeutics

  2016cites this paper
• Viro-immune therapy: A new strategy for treatment of pancreatic cancer.

  2016cites this paper
• Oncolytic virotherapy using herpes simplex virus: how far have we come?

  2015cites this paper
• Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens.

  2014cites this paper
• A Novel Selection Technology for the Discovery of High-Affinity Human Proteins

  2014cites this paper
• Selectively Replicating Herpes Simplex Viral Vectors

  2014cites this paper
• Herpes Simplex Virus 1 (HSV-1)-Based Vectors

  2014cites this paper
• Regulation of adenovirus replication by miR-199 confers a selective oncolytic activity in hepatocellular carcinoma

  2012cites this paper
• Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.

  2012cites this paper
• Targetting and Arming Oncolytic Viruses

  2012influential citation
• Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy

  2012cites this paper
• Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors

  2011cites this paper
• Engineered herpes simplex virus vectors for antitumor therapy and vaccine delivery

  2011cites this paper
• HSV Recombinant Vectors for Gene Therapy.

  2010cites this paper
• ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.

  2010cites this paper
• Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles

  2010cites this paper
• Targeting human glioma cells using HSV-1 amplicon peptide display vector

  2010cites this paper
• Mutation of Herpesvirus Saimiri ORF51 Glycoprotein Specifically Targets Infectivity to Hepatocellular Carcinoma Cell Lines

  2010cites this paper
• HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases.

  2010cites this paper
• Assessment and development of adenovirus type 11 for cancer therapy

  2010cites this paper
• HSV Recombinant Vectors for Gene Therapy

  2010cites this paper
• A lentiviral vector‐based adenovirus fiber‐pseudotyping approach for expedited functional assessment of candidate retargeted fibers

  2009cites this paper
• Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells

  2009cites this paper
• Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy.

  2009cites this paper
• Journal of Hepatocellular Carcinoma Dovepress Potent Efficacy Signals from Systemically Administered Oncolytic Herpes Simplex Virus (hsv1716) in Hepatocellular Carcinoma Xenograft Models

  year unknowncites this paper